Transplanting bioengineered human lung organoids into mice could lead to a humanized model for pre-clinical studies of lung disease.
The human airways bring air into and out of the lungs, and the epithelium that lines these airways uses a combination of mucus and hair-like structures called cilia to clear inhaled particles and microorganisms from the lungs. For decades cell biologists have been able to make mature airway epithelia in vitro by taking airway cells from patients and cadavers and growing them in culture. These epithelia have been used for a range of applications, from fundamental cell biology and cancer genetics to clinical diagnosis and pharmacological testing (discussed in Fulcher et al., 2005). In recent years researchers have been trying to use human pluripotent stem cells – cells that can differentiate to become any of the types of cells that are found in the body – to make mature airway epithelia. However, if such epithelia are available from real people, potentially with a complete medical history, why is there any interest in using pluripotent stem cells to make them?
The answer is two-fold. First, the adult epithelia grown in culture suffer from various limitations: they are highly variable, they contain only a limited range of cell types, and it is not possible to introduce targeted genetic mutations in them, although numerous labs are working to solve these issues (Mou et al., 2016; Butler et al., 2016). Second, the use of pluripotent stem cells to make mature airway epithelia has the attraction of allowing researchers to study the progressive development of a disease over time. In addition, the use of pluripotent stem cell lines will make it possible to introduce a specific genetic alteration and study its effect by comparing these cell lines to otherwise genetically identical control cells. Reproducible growth of epithelia with these features has the potential to improve disease modeling, to facilitate drug discovery across a range of lung diseases, and to provide a limitless supply of cells for toxicology testing, or even for regenerative medicine. However, while there have been numerous reports of methods for producing mature airway epithelia from pluripotent stem cells, the cells in these epithelia have tended to resemble embryonic and neonatal cells rather than mature adult cells.
The airways and lungs are derived from a region in the developing embryo called the anterior foregut endoderm. A typical method for making mature epithelia from stem cells involves starting with pluripotent stem cells and coaxing them to become endoderm cells, then anterior foregut endoderm cells, then lung progenitor cells (which can become any type of lung cell) and, finally, various types of airway epithelial cells. One recent innovation involved the growth of three-dimensional structures called human lung organoids by a group at the University of Michigan (Dye et al., 2015) and another group at Kyoto Univerisity and Osaka University (Konishu et al., 2016). These organoids contained many of the cell types that are found in mature airway epithelia but, notably, they did not contain mature goblet cells (the cells that produce mucus) or a number of other secretory cells (Figure 1A). Now, building on their previous work, Jason Spence of the University of Michigan and co-workers – including Briana Dye as first author – report that these shortcomings can be overcome by using a combination of synthetic "scaffolds" and in vivo growth in mice (Dye et al., 2016).
It has become a standard technique to implant immature organoids (or cells derived from pluripotent stem cells) into well-vascularized sites in mice whose immune system has been compromised. The growth of the cells in this in vivo environment, typically in the kidney capsule or in fatty tissue adjacent to the stomach or epididymis, helps them to mature properly, presumably due to the physiological levels of nutrients, oxygen and circulating factors. Dye et al. started by taking human lung organoids that had been grown in a basement membrane substrate (Matrigel) and implanting them directly into the mice. Although human epithelia were recovered from these initial transplants, they rarely contained lung cells.
In an attempt to solve this problem Dye et al. decided to first culture the organoids on synthetic scaffolds made of a polymer called Poly(lactide-co-glycolide), which is used in medical devices and for culturing pancreatic cells (Yap et al., 2013). Given the size of the scaffolds, the only suitable transplantation site was the fat pad adjacent to the epididymis (which is near the testicles in male mice). When the scaffolds were retrieved from the mice, typically following 8–15 weeks of growth in vivo, the organoids had frequently grown into tubes that resembled the adult airway and, moreover, they contained a wider range of mature cell types than had been produced before (Figure 1B). Importantly, this latter finding was validated by detailed comparison to human fetal and adult airways.
The in vivo system developed by Dye, Spence and co-workers appears to be reproducible across multiple pluripotent cell lines and could be used to develop improved models of adult lung diseases and for pre-clinical drug testing. And if we can learn more about the mechanisms that underlie the maturation process, it might be possible to produce mature epithelia in vitro for high-throughput (drug discovery-type) experiments. It will also be important to assess whether mature alveoli (the lung cells that are involved in the exchange of oxygen and carbon dioxide) can be generated from pluripotent stem cells through similar in vivo transplantation approaches. Further study is also needed to assess how different types of scaffolds affect the maturation of cells in vivo.
Rapid expansion of human epithelial stem cells suitable for airway tissue engineeringAmerican Journal of Respiratory and Critical Care Medicine 194:156–168.https://doi.org/10.1164/rccm.201507-1414OC
Well-differentiated human airway epithelial cell culturesMethods in Molecular Medicine 107:183–206.https://doi.org/10.1385/1-59259-861-7:183
Collagen IV-modified scaffolds improve islet survival and function and reduce time to euglycemiaTissue Engineering Part A 19:2361–2372.https://doi.org/10.1089/ten.tea.2013.0033
Downloads (link to download the article as PDF)
Download citations (links to download the citations from this article in formats compatible with various reference manager tools)
Open citations (links to open the citations from this article in various online reference manager services)
Developmental studies revealed fundamental principles on how organ size and function is achieved, but less is known about organ adaptation to new physiological demands. In fruit flies, juvenile hormone (JH) induces intestinal stem cell (ISC) driven absorptive epithelial expansion balancing energy uptake with increased energy demands of pregnancy. Here, we show 20-Hydroxy-Ecdysone (20HE)-signaling controlling organ homeostasis with physiological and pathological implications. Upon mating, 20HE titer in ovaries and hemolymph are increased and act on nearby midgut progenitors inducing Ecdysone-induced-protein-75B (Eip75B). Strikingly, the PPARγ-homologue Eip75B drives ISC daughter cells towards absorptive enterocyte lineage ensuring epithelial growth. To our knowledge, this is the first time a systemic hormone is shown to direct local stem cell fate decisions. Given the protective, but mechanistically unclear role of steroid hormones in female colorectal cancer patients, our findings suggest a tumor-suppressive role for steroidal signaling by promoting postmitotic fate when local signaling is deteriorated.
Adult neural stem cells, located in discrete brain regions, generate new neurons throughout life. These stem cells are specialized astrocytes, but astrocytes in other brain regions do not generate neurons under physiological conditions. After stroke, however, striatal astrocytes undergo neurogenesis in mice, triggered by decreased Notch signaling. We used single-cell RNA sequencing to characterize neurogenesis by Notch-depleted striatal astrocytes in vivo. Striatal astrocytes were located upstream of neural stem cells in the neuronal lineage. As astrocytes initiated neurogenesis, they became transcriptionally very similar to subventricular zone stem cells, progressing through a near-identical neurogenic program. Surprisingly, in the non-neurogenic cortex, Notch-depleted astrocytes also initiated neurogenesis. Yet, these cortical astrocytes, and many striatal ones, stalled before entering transit-amplifying divisions. Infusion of epidermal growth factor enabled stalled striatal astrocytes to resume neurogenesis. We conclude that parenchymal astrocytes are latent neural stem cells and that targeted interventions can guide them through their neuronal differentiation.